Data from phase 2 clinical trials have shown that Eprenetapopt in combination with azacytidine yields high response rates (73%) in TP53-mutated MDS patients, with 50% achieving complete remission and 58% a cytogenic response [188]. This evidence concerns the gene TP53 and myelodysplastic syndrome.